384 related articles for article (PubMed ID: 9305636)
1. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
3. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
4. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
5. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
6. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
7. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
Chang H; Riese DJ; Gilbert W; Stern DF; McMahan UJ
Nature; 1997 May; 387(6632):509-12. PubMed ID: 9168114
[TBL] [Abstract][Full Text] [Related]
8. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
9. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Vadlamudi R; Mandal M; Adam L; Steinbach G; Mendelsohn J; Kumar R
Oncogene; 1999 Jan; 18(2):305-14. PubMed ID: 9927187
[TBL] [Abstract][Full Text] [Related]
11. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.
Carraway KL; Weber JL; Unger MJ; Ledesma J; Yu N; Gassmann M; Lai C
Nature; 1997 May; 387(6632):512-6. PubMed ID: 9168115
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ
Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction and oncogenesis by ErbB/HER receptors.
Marmor MD; Skaria KB; Yarden Y
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):903-13. PubMed ID: 14967450
[TBL] [Abstract][Full Text] [Related]
14. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) signaling in cancer.
Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
17. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP; Dempsey PJ; Dunbar AJ
Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
19. Type I growth factor receptors: current status and future work.
Gullick WJ
Biochem Soc Symp; 1998; 63():193-8. PubMed ID: 9513723
[TBL] [Abstract][Full Text] [Related]
20. Affinity regulates spatial range of EGF receptor autocrine ligand binding.
DeWitt A; Iida T; Lam HY; Hill V; Wiley HS; Lauffenburger DA
Dev Biol; 2002 Oct; 250(2):305-16. PubMed ID: 12376105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
